Desmond Curran

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 59

Top Venues

Infectious diseases and therapy

Human vaccines & immunotherapeutics

Clinical drug investigation

Influenza and other respiratory viruses

GLAXOSMITHKLINE

Universiteit Hasselt (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

GLAXOSMITHKLINE Aug 01 2012

Belgium

Global Director of Health Economics :: Value Evidence

OMEGA RESEARCH Aug 01 2004 - Jul 31 2012

Ireland

CEO

ICON plc Jan 01 2000 - Jul 31 2004

Ireland

Associate Director of Biostatistics :: Statistics

European Organisation for Research and Treatment of Cancer Dec 01 1993 - Dec 31 1999

Belgium

Statistician :: Statistics

Education History

Universiteit Hasselt Sep 01 1995 - May 31 2000

Belgium

PHD :: Statistics

Dublin City University Sep 01 1986 - May 31 1991

Ireland

BSC :: Applied Mathematics

Publications

Nikolaos Giannelos, Bernard G Francq, Desmond Curran
Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials. Clinical drug investigation 44 (5) (2024)
Nikolaos Giannelos, Bernard G Francq, Desmond Curran
Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials. Clinical drug investigation 44 (5) (2024)
Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review. Infectious diseases and therapy 13 (3) (2024)
Nikolaos Giannelos, Desmond Curran, Chi Nguyen, Carol Kagia, Nikki Vroom, Hilde Vroling
The Incidence of Herpes Zoster Complications: A Systematic Literature Review. Infectious diseases and therapy (2024)
Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera, Silvia Narejos Pérez, Lina Pérez Breva, Mika Rämet, Laura Helman, Dae Won Park, Tino F Schwarz, Isabel Maria Galan Melendez, Axel Schaefer, Nathalie Roy, Brigitte Stephan, Daniel Molnar, Lusine Kostanyan, John H Powers, Veronica Hulstrøm, null null
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. Influenza and other respiratory viruses 18 (2) (2024)
Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review. Infectious diseases and therapy 13 (3) (2024)
Desmond Curran, Jacopo Bitetti, Imogen Catterall, Stephen Wincott
Herpes zoster in older adults: Impact on carbon footprint in the United States. Human vaccines & immunotherapeutics 20 (1) (2024)
Nikolaos Giannelos, Bernard G Francq, Desmond Curran
Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials. Clinical drug investigation 44 (5) (2024)
Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review. Infectious diseases and therapy (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Desmond Curran, Jacopo Bitetti, Imogen Catterall, Stephen Wincott
Herpes zoster in older adults: Impact on carbon footprint in the United States. Human vaccines & immunotherapeutics 20 (1) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Nikolaos Giannelos, Desmond Curran, Chi Nguyen, Carol Kagia, Nikki Vroom, Hilde Vroling
The Incidence of Herpes Zoster Complications: A Systematic Literature Review. Infectious diseases and therapy 13 (7) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review. Infectious diseases and therapy 13 (3) (2024)
Desmond Curran, Jacopo Bitetti, Imogen Catterall, Stephen Wincott
Herpes zoster in older adults: Impact on carbon footprint in the United States. Human vaccines & immunotherapeutics 20 (1) (2024)
Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera, Silvia Narejos Pérez, Lina Pérez Breva, Mika Rämet, Laura Helman, Dae Won Park, Tino F Schwarz, Isabel Maria Galan Melendez, Axel Schaefer, Nathalie Roy, Brigitte Stephan, Daniel Molnar, Lusine Kostanyan, John H Powers, Veronica Hulstrøm
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. Influenza and other respiratory viruses 18 (2) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Nikolaos Giannelos, Bernard G Francq, Desmond Curran
Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials. Clinical drug investigation 44 (5) (2024)
Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera, Silvia Narejos Pérez, Lina Pérez Breva, Mika Rämet, Laura Helman, Dae Won Park, Tino F Schwarz, Isabel Maria Galan Melendez, Axel Schaefer, Nathalie Roy, Brigitte Stephan, Daniel Molnar, Lusine Kostanyan, John H Powers, Veronica Hulstrøm
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. Influenza and other respiratory viruses 18 (2) (2024)
Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review. Infectious diseases and therapy 13 (3) (2024)
Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review. Infectious diseases and therapy 13 (3) (2024)
Nikolaos Giannelos, Bernard G Francq, Desmond Curran
Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials. Clinical drug investigation 44 (5) (2024)
Nikolaos Giannelos, Desmond Curran, Chi Nguyen, Carol Kagia, Nikki Vroom, Hilde Vroling
The Incidence of Herpes Zoster Complications: A Systematic Literature Review. Infectious diseases and therapy 13 (7) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Nikolaos Giannelos, Bernard G Francq, Desmond Curran
Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials. Clinical drug investigation (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy (2024)
Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera, Silvia Narejos Pérez, Lina Pérez Breva, Mika Rämet, Laura Helman, Dae Won Park, Tino F Schwarz, Isabel Maria Galan Melendez, Axel Schaefer, Nathalie Roy, Brigitte Stephan, Daniel Molnar, Lusine Kostanyan, John H Powers, Veronica Hulstrøm
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. Influenza and other respiratory viruses 18 (2) (2024)
Nikolaos Giannelos, Desmond Curran, Chi Nguyen, Carol Kagia, Nikki Vroom, Hilde Vroling
The Incidence of Herpes Zoster Complications: A Systematic Literature Review. Infectious diseases and therapy 13 (7) (2024)
Nikolaos Giannelos, Desmond Curran, Chi Nguyen, Carol Kagia, Nikki Vroom, Hilde Vroling
The Incidence of Herpes Zoster Complications: A Systematic Literature Review. Infectious diseases and therapy 13 (7) (2024)
Nikolaos Giannelos, Desmond Curran, Chi Nguyen, Carol Kagia, Nikki Vroom, Hilde Vroling
The Incidence of Herpes Zoster Complications: A Systematic Literature Review. Infectious diseases and therapy 13 (7) (2024)
Ahmed Ehab Salem, Elizabeth M La, Desmond Curran, Brandon J Patterson, Justin Carrico, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter
Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States. PharmacoEconomics - open (2023)
Nikolaos Giannelos, Cheryl Ng, Desmond Curran
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Human vaccines & immunotherapeutics (2023)
Desmond Curran, Brandon J Patterson, Justin Carrico, Ahmed Ehab Salem, Elizabeth M La, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Human vaccines & immunotherapeutics (2023)
Nikolaos Giannelos, Cheryl Ng, Desmond Curran
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Human vaccines & immunotherapeutics 19 (1) (2023)
Desmond Curran, Brandon J Patterson, Justin Carrico, Ahmed Ehab Salem, Elizabeth M La, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Human vaccines & immunotherapeutics 19 (1) (2023)
Desmond Curran, Brandon J Patterson, Justin Carrico, Ahmed Ehab Salem, Elizabeth M La, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Human vaccines & immunotherapeutics 19 (1) (2023)
Desmond Curran, Brandon J Patterson, Justin Carrico, Ahmed Ehab Salem, Elizabeth M La, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Human vaccines & immunotherapeutics 19 (1) (2023)
Agnes Mwakingwe-Omari, Nicolas Lecrenier, Abdi Naficy, Desmond Curran, Inga Posiuniene
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies. Human vaccines & immunotherapeutics 19 (3) (2023)
Desmond Curran, Brandon J Patterson, Justin Carrico, Ahmed Ehab Salem, Elizabeth M La, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Human vaccines & immunotherapeutics 19 (1) (2023)
Desmond Curran, Elizabeth M La, Ahmed Ehab Salem, David Singer, Nicolas Lecrenier, Sara Poston
Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States. Human vaccines & immunotherapeutics 18 (1) (2022)
Lida Teng, Akiko Mizukami, Cheryl Ng, Nikolaos Giannelos, Desmond Curran, Tomohide Sato, Christa Lee, Taizo Matsuki
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults. Dermatology and therapy 12 (6) (2022)
Desmond Curran, Sean Matthews, Céline Boutry, Nicolas Lecrenier, Anthony L Cunningham, Kenneth E Schmader
Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials. Infectious diseases and therapy 11 (6) (2022)
Desmond Curran, Eliazar Sabater Cabrera, Benjamin Bracke, Kimberly Raymond, April M Foster, Cindy Umanzor, Philibert Goulet, John H Powers
Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross-sectional study. Influenza and other respiratory viruses 16 (3) (2022)
Désirée A M van Oorschot, Hilde Vroling, Eveline M Bunge, John D Diaz-Decaro, Desmond Curran, Barbara P Yawn
A systematic literature review of herpes zoster incidence worldwide. Human vaccines & immunotherapeutics 17 (6) (2021)
Desmond Curran, Andrea Callegaro, Kyle Fahrbach, Binod Neupane, Hilde Vroling, Désirée A M van Oorschot, Barbara P Yawn
Meta-Regression of Herpes Zoster Incidence Worldwide. Infectious diseases and therapy (2021)
Desmond Curran, Désirée A M van Oorschot, Sean Matthews, Johannes Hain, Ahmed Ehab Salem, Magdalena Schwarz
Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Human vaccines & immunotherapeutics 17 (12) (2021)
Desmond Curran, Eliazar Sabater Cabrera, Linda M Nelsen
Patient-reported outcomes in vaccines research: relevance for decision-making. Human vaccines & immunotherapeutics (2021)
Javier Diez-Domingo, Desmond Curran, Maria Del Rosario Cambronero, Juan-Antonio Garcia-Martinez, Sean Matthews
Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study. Advances in therapy 38 (6) (2021)
Christa Lee, Ning Jiang, Haiwen Tang, Chiyu Ye, Yanfei Yuan, Desmond Curran
Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Human vaccines & immunotherapeutics 17 (10) (2021)
Desmond Curran, Joon H Kim, Sean Matthews, Christophe Dessart, Myron J Levin, Lidia Oostvogels, Megan E Riley, Kenneth E Schmader, Anthony L Cunningham, Shelly A McNeil, Anne E Schuind, Melissa K Andrew, null null
Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. Journal of the American Geriatrics Society 69 (3) (2020)
Mohamed Neine, Desmond Curran
An algorithm to generate correlated input-parameters to be used in probabilistic sensitivity analyses. Journal of market access & health policy 9 (1) (2020)
Desmond Curran, Melissa K Andrew, Myron J Levin, Elisa Turriani, Sean Matthews, Charles Fogarty, Nicola P Klein, Katrijn Grupping, Lidia Oostvogels, Kenneth E Schmader
Evaluation of two frailty indices, with practical application in a vaccine clinical trial. Human vaccines & immunotherapeutics 15 (12) (2019)
Desmond Curran, Manjit Hunjan, Amale El Ghachi, Yassine El-Hahi, Veronique Bianco, Germano Ferreira
Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. BMJ open 9 (8) (2019)
Sean Matthews, Antonio De Maria, Marco Passamonti, Giovanni Ristori, Idalba Loiacono, Anna Puggina, Desmond Curran
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. Open forum infectious diseases 6 (2) (2019)
Désirée A M van Oorschot, Manjit Hunjan, Benjamin Bracke, Stéphane Lorenc, Desmond Curran, Helen Starkie-Camejo
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ open 9 (5) (2019)
Antonio Volpi, Sara Boccalini, Silvia Dari, Christopher Clarke, Desmond Curran, Idalba Loiacono, Andrea Pitrelli, Anna Puggina, Roberta Tosatto, Desirée Van Oorschot, Elisabetta Franco
The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. Human vaccines & immunotherapeutics 16 (2) (2019)
Desmond Curran, Brandon J Patterson, Desiree Van Oorschot, Philip O Buck, Justin Carrico, Katherine A Hicks, Bruce Lee, Barbara P Yawn
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Human vaccines & immunotherapeutics 15 (4) (2019)
Desmond Curran, Ruprecht Schmidt-Ott, Ulf Schutter, Jörg Simon, Anastassia Anastassopoulou, Sean Matthews
Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC infectious diseases 18 (1) (2018)

Desmond Curran.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Desmond Curran